ID Management A/S’s Enanta Pharmaceuticals ENTA Stock Holding History

ID Management A/S’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,000	Closed	-$102K	–	285
2014 Q4	$102K	Buy	2,000 +900	+82%	+$40.3K	0.05%	232
2014 Q3	$44K	Buy	+1,100	New	+$43.8K	0.02%	258

Other funds holding ENTA

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MVM

McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ID Management A/S's ENTA Position: Q1 2015 in Review

ID Management A/S sold out of Enanta Pharmaceuticals (ENTA) in Q1 2015, closing a stake of 2,000 shares — an estimated $102K sold.

ID Management A/S first reported a position in ENTA in Q3 2014 and held it in 2 quarters. The position peaked at $102K in Q4 2014. 117 funds tracked by Wall St. Rank hold ENTA as of Q1 2015.

ID Management A/S reported no remaining Enanta Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
ID Management A/S sold 2,000 Enanta Pharmaceuticals shares in Q1 2015, an estimated $102K.
ID Management A/S first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 2 quarters.
ID Management A/S's Enanta Pharmaceuticals position peaked at $102K in Q4 2014.
117 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2015.

Based on ID Management A/S's 13F filing for Q1 2015, filed 22 Apr 2015.